Management of Cardio-Renal-Anemia Syndrome

Heart Failure Management

The American Journal of Kidney Diseases recommends treating heart failure according to standard guidelines despite CKD, as the level of care for heart failure should be the same as offered to those without CKD 5, 6
Diuretic therapy should be used to manage fluid overload and congestion, with careful monitoring of renal function and electrolytes, as suggested by the American Journal of Kidney Diseases 5, 7
The American Journal of Kidney Diseases suggests considering higher doses of loop diuretics due to decreased renal function, with twice daily dosing preferred over once daily for better efficacy 7
Dietary sodium intake should be restricted to <2.0 g/day to enhance diuretic efficacy, as recommended by the American Journal of Kidney Diseases 7
The American Journal of Kidney Diseases recommends monitoring for diuretic resistance; if present, consider combination therapy with different classes of diuretics 7
For patients with HF and CKD, any escalation in therapy or clinical deterioration should prompt monitoring of eGFR and serum potassium, as suggested by the American Journal of Kidney Diseases 5, 6

The Kidney International journal recognizes that AKI on CKD increases mortality risk and requires careful monitoring 3
Nephrotoxic agents should be discontinued when possible, as recommended by the Kidney International journal 3
Adequate volume status and perfusion pressure should be ensured while avoiding overhydration, as suggested by the Kidney International journal 3
Serum creatinine should be monitored regularly, as recommended by the Kidney International journal 3
Medication dosing should be adjusted based on current kidney function, as suggested by the Kidney International journal 3
The Annals of Internal Medicine recommends considering ACEi or ARB therapy for patients with both hypertension and proteinuria unless contraindicated 8, 7
The American Journal of Kidney Diseases suggests being vigilant about hyperkalemia risk with RAAS blockade, especially with dual blockade 5

The American Journal of Hematology recommends treating iron deficiency with intravenous iron supplementation as the first-line therapy for patients with heart failure and CKD 4
Erythropoiesis-stimulating agents (ESAs) should be considered if anemia persists after iron repletion, particularly with eGFR <60 ml/min/1.73m², as suggested by the American Journal of Hematology 4
Hemoglobin response to therapy should be monitored, as recommended by the American Journal of Hematology 4
Blood transfusions should be considered for severe symptomatic anemia, as suggested by the American Journal of Hematology 4
The American Journal of Hematology recommends investigating for potential gastrointestinal sources of blood loss when the patient is stable 4

Fluid status should be monitored through daily weights, input/output measurements, and physical examination, as recommended by the Metabolism: Clinical and Experimental journal 1
Electrolytes, BUN, and creatinine should be checked regularly, especially after changes in diuretic therapy, as suggested by the American Journal of Kidney Diseases and Kidney International journals 5, 3
Hemoglobin response to iron therapy and/or ESAs should be monitored, as recommended by the American Journal of Hematology 4
Cardiac biomarkers (BNP/NT-proBNP) should be assessed with caution, as levels are affected by reduced GFR, as suggested by the American Journal of Kidney Diseases 5, 6
Signs of worsening heart failure or kidney function should be monitored, as recommended by the American Journal of Kidney Diseases and Metabolism: Clinical and Experimental journals 5, 1

Cardiac biomarkers (BNP/NT-proBNP) should be interpreted with caution in patients with GFR <60 ml/min/1.73m², as suggested by the American Journal of Kidney Diseases 5, 6
Troponin levels should also be interpreted cautiously with respect to diagnosis of acute coronary syndrome in CKD patients, as recommended by the American Journal of Kidney Diseases 5, 6
Iron deficiency in heart failure can occur with normal ferritin levels due to inflammation, as noted by the American Journal of Hematology 4
Dual RAAS blockade should be avoided due to increased risk of hyperkalemia and AKI, as recommended by the American Journal of Kidney Diseases 5
The risk of contrast-induced AKI should be balanced against the potential benefits when considering invasive cardiac procedures, as suggested by the Journal of the American College of Cardiology and American Journal of Kidney Diseases 9, 2